Current Research & Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy

Summary Table A: Global CAR T-Cell Market, by Region, Through 2026
Summary Table B: Global CAR T-Cell Market, by Product, Through 2026
Table 1: Tumor-Associated Antigens of CAR T-Cell Targets
Table 2: List of Relevant Human Clusters of Differentiation
Table 3: Classification of Natural Killer T Cells
Table 4: Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues
Table 5: Tumor-Associated Antigens of CAR T-Cell Target
Table 6: Reported COVID-19 Confirmed Cases and Deaths, by Country, October 22, 2021
Table 7: Supplementary Components in CAR T-Cell Manufacture
Table 8: Technologies Used in the Selection, Isolation and Enrichment of Cells During the Manufacture of CAR T Cells
Table 9: Technologies Used in the Activation and Simulation of Cells During the Manufacture of CAR T Cells
Table 10: Technologies Used in the Gene Transfer and Delivery of Cells During the Manufacture of CAR T Cells
Table 11: Gene Transfer and Gene Delivery Technologies Developed by Poseida Therapeutics Inc.
Table 12: Technologies Used in the Expansion and Culture of Cells During the Manufacture of CAR T Cells
Table 13: Technologies Used in the Formulation of Cells During the Manufacture of CAR T Cells
Table 14: Technologies Used in the Cryopreservation of Cells During the Manufacture of CAR T Cells
Table 15: Technologies Used in the Thawing of Cells During the Manufacture of CAR T Cells
Table 16: Emerging CAR T-Cell Therapy Clinical Trials, by Company
Table 17: Global CAR T-Cell Clinical Trial Activity, by Study Location/Region, as of Oct. 2021
Table 18: Clinical Trials on CD19 Directed CAR T-Cells in the U.S.
Table 19: Examples of Clinical Trials on CD19-Directed CAR T Cells in China
Table 20: Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China
Table 21: Examples of Clinical Trials on CAR T Cells for Solid Tumors in China
Table 22: Clinical Trials on CAR T Cells with Fourth-Generation CARs in China
Table 23: Global Cancer Incidence, by Cancer Type/Site, 2020
Table 24: Global Cancer Mortality, by Cancer Type/Site, 2020
Table 25: Estimated Number of New Cancer Cases in the U.S., by Cancer Type/Site and Sex, 2021
Table 26: Estimated Number of Cancer Deaths in the U.S., by Cancer Type/Site and Sex, 2021
Table 27: Global CAR T-Cell Market, by Product, 2026
Table 28: Global CAR T-Cell Market, by Region, Through 2026
Table 29: Global CAR T-Cell Market Share, by Region, 2021
Table 30: North American CAR T-Cell Market, Through 2026
Table 31: North American CAR T-Cell Market, by Product, Through 2026
Table 32: European CAR T-Cell Market, Through 2023
Table 33: European CAR T-Cell Market, by Product, Through 2026
Table 34: Asia-Pacific CAR T-Cell Market, Through 2023
Table 35: Asia-Pacific CAR T-Cell Market, by Product, Through 2026
Table 36: Rest of the World CAR T-Cell Market, Through 2020-2026
Table 37: Rest of the World CAR T-Cell Market, by Product, Through 2026
Table 38: Overview of Healthcare System in India
Table 39: Recent CAR T-Cell Therapy Patents and Patent Applications, 2020-2021
Table 40: Recent Bluebird Bio Patents and Patent Applications, 2010-Apr. 2021
Table 41: Recent Celgene Patents and Patent Applications, 2018-2021
Table 42: Recent Cellectis Patents and Patent Applications, 2018-2021
Table 43: Editas Medicine Patent Applications, 2010-2021
Table 44: Eureka Therapeutics Patent Applications, 2015-2021
Table 45: Kite Pharma’s (Gilead Sciences Subsidiary) Core Anticancer Technology: Yeda Research and Development Co., Ltd. Patents and Patent Applications, 1993-Apr. 2021
Table 46: iCell Gene Therapeutics Patent Applications
Table 47: Juno Therapeutics Inc. and Memorial Sloan Kettering Patents and Patent Applications
Table 48: Mustang Bio and City of Hope National Medical Center Patents and Patent Applications
Table 49: Noile-Immune Biotech Inc. Yamaguchi University Patent Applications
Table 50: Novartis AG and University of Pennsylvania Patents and Patent Applications, 2013-2021
Table 51: Global CAR T-Cell Market Share, by Company, 2021
Table 52: Global CAR T-Cell Therapy Market, by Company Revenue, 2018-2021
Table 53: New Product Launches in the CAR T-Cell Therapy Market
Table 54: New Strategic Initiatives in CAR T-Cell Therapy Market
Table 55: Mergers and Acquisitions in the CAR T-Cell Therapy Market, 2018-2021
Table 56: Regulatory Approvals in the CAR T-Cell Therapy Market, 2018-2021
Table 57: AbbVie Inc.: Marketed Products
Table 58: AbbVie Inc.: Net Revenue, 2017-2020
Table 59: AbbVie Inc.: Key Developments
Table 60: Amgen: Financials, 2014-2020
Table 61: Amgen: Financials, by Product, 2014-2020
Table 62: Avacta Group plc: Financials, 2015-2017
Table 63: Bellicum Pharmaceuticals Inc.: Financials, 2019 and 2020
Table 64: Bellicum Pharmaceuticals Inc.: Key Switch Technologies
Table 65: Bluebird Bio: Financials, 2018-2020
Table 66: Bluebird Bio: Key Developments
Table 67: Bristol-Myers Squibb: Net Revenue, 2017-2020
Table 68: Bristol-Myers Squibb: Key Cancer Biologics Product Portfolio
Table 69: Bristol-Myers Squibb: Key Developments
Table 70: Juno Therapeutics: Product Pipeline
Table 71: Editas Medicine Inc.: Financials, 2015-2020
Table 72: Editas Medicine Inc.: Key Developments
Table 73: Gilead Sciences: Financials, 2014-2020
Table 74: Gilead Sciences: Key CAR T-Cell Therapies
Table 75: Gilead Sciences: Individual Product Sales, 2018-2020
Table 76: Gilead Sciences: Product Pipeline
Table 77: F. Hoffman-La Roche: Financials, 2019 and 2020
Table 78: F. Hoffman-La Roche: Pharmaceutical Division Financials, 2019 and 2020
Table 79: F. Hoffman-La Roche: Total Revenue, by Geography, 2020
Table 80: iCell Gene Therapeutics: Product Development Pipeline
Table 81: Mustang Bio Inc.: Research and Development Pipeline
Table 82: Novartis AG: Revenues, by Segment, 2019 and 2020
Table 83: Protheragen: Enabling Technologies
Table 84: PureTech Health: Immune System Pipeline
Table 85: Takeda Pharmaceuticals: Financials, 2014-2016
Table 86: Company Contact Details
Table 87: Government Regulatory Agencies and Professional Organizations Associated with CAR T-Cell Therapy
Table 88: Commonly Used Acronyms Associated with CAR T-Cell Therapy
Table 89: Recent Patent Applications Filed Related to CAR T-Cell Therapy
Table 90: CAR T-Cell and CD19 Clinical Trials in China

Summary Figure A: Global CAR T-Cell Market Share, by Region, 2021
Summary Figure B: Global CAR T-Cell Market, by Product, 2018-2026
Summary Figure C: Global CAR T-Cell Clinical Trials, by Phase, as of October 2021
Figure 1: Historical Development of CAR T-Cell Therapy
Figure 2: Cytotoxic T-Cell Activation and Action
Figure 3: Overview of Signal Transduction Pathways Involved in Apoptosis
Figure 4: Model for Th Differentiation from Naïve CD4+ T Cells
Figure 5: Diagram of Regulatory T Cell, Effector T Cells and Dendritic Cells Showing Putative Mechanisms of Suppression by Regulatory T Cells
Figure 6: Interactions and Cross-Talk Between Different Subsets of NKT Cells and Other Immune Cells in TME
Figure 7: Schematic of Adoptive Cell Transfer Therapies
Figure 8: Structure and Function of the TCR
Figure 9: General Structure of a Chimeric Antigen Receptor
Figure 10: CAR T-Cell Design
Figure 11: CAR T-Cell Manufacture and Product Testing Process
Figure 12: Sleeping Beauty (SB) Transposon System Mechanism Schematic
Figure 13: PiggyBac (PB) Transposon System “Cut and Paste” Mechanism Schematic
Figure 14: CRISPR/Cas9 System Mechanism Schematic
Figure 15: Global CAR T-Cell Clinical Trial Activity, by Phase, as of Oct. 2021
Figure 16: Global CAR T-Cell Clinical Trial Activity, by Study Start Date and Phase, 2005-Oct. 2021
Figure 17: Distribution Map of CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of Oct. 2021
Figure 18: Distribution Map of CAR T-Cell Clinical Trial Activity in Europe, by Study Location/Country, as of Oct. 2021
Figure 19: Distribution Map of Phase I CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of Oct. 2021
Figure 20: Distribution Map of Phase II CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of Oct. 2021
Figure 21: Distribution Map of Phase III CAR T-Cell Clinical Trial Activity Globally, by Study Location/Country, as of Oct. 2021
Figure 22: Distribution Map of CAR T-Cell Clinical Trial Activity in the U.S., by Study Location, as of Oct. 2021
Figure 23: Distribution of CAR T-Cell Clinical Trials in China, South Korea and Taiwan, by Study Location/Region, as of Oct. 2021
Figure 24: CAR T-Cell Clinical Trials in China, by Study Start Date and Phase, 2006-Oct. 2021
Figure 25: Global Cancer Incidence, by Sex and Cancer Type/Site, 2020
Figure 26: Global Cancer Incidence, by Region, 2020
Figure 27: Global Cancer Incidence Trends, by Cancer Type/Site, 2020-2030
Figure 28: Global Cancer Prevalence by Cancer Type/Site and Sex, 2020
Figure 29: Global CAR T-Cell Market, by Product, 2018-2026
Figure 30: Global Market for Yescarta Cell Therapy, by Region, 2017-2021
Figure 31: Global Market Shares of Yescarta Cell Therapy, by Region, 2020
Figure 32: Global Market for Tecartus, by Region, 2020-2021
Figure 33: Global Market Shares of Tecartus, by Region, 2020
Figure 34: Global Market for Kymriah, by Region, 2017-2021
Figure 35: Global Market Shares of Kymriah, by Region, 2020
Figure 36: Global CAR T-Cell Market Share, by Region, 2021
Figure 37: Drug Discovery and Development Timeline
Figure 38: Mutual Recognition Procedure
Figure 39: Decentralized Procedure
Figure 40: Japanese Drug Funding/Reimbursement Approval Procedure
Figure 41: The Chinese Healthcare System
Figure 42: Argentina: Regulatory Drug Approval Procedure Standard Review 120-240 Business Days* for Approval**
Figure 43: Current Structure of the Health Care Sector in Saudi Arabia
Figure 44: Global CAR T-Cell Therapy Market Share, by Company, 2021
Figure 45: AbbVie Inc.: Revenue Share, by Country, 2020
Figure 46: Bellicum Pharmaceuticals Inc.: Product Pipeline
Figure 47: Bristol-Myers Squibb: Revenue Share, by Segment, 2020
Figure 48: Bristol-Myers Squibb: Revenue Share, by Region, 2020
Figure 49: Cellectis: Allogeneic CAR-T Pipeline
Figure 50: Eureka Therapeutics Inc.: Product Pipeline
Figure 51: Formula Pharmaceuticals Inc.: Product Pipeline
Figure 52: Kite Pharma Inc. (a Subsidiary of Gilead Sciences Inc.): CAR and TCR Pipeline
Figure 53: Noile-Immune Biotech: CAR Pipeline
Figure 54: Novartis AG: Sales Prediction for Kymriah
Figure 55: Protheragen: Product Pipeline